

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

**(1) POLL RESULTS OF
THE 2026 FIRST EXTRAORDINARY GENERAL MEETING
HELD ON OCTOBER 9, 2026;**

**(2) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
(3) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
AND**

(4) CHANGE OF COMPOSITION OF BOARD COMMITTEES

The Board is pleased to announce that the resolution set out in the Notice was duly passed by the Shareholders by way of poll at the EGM.

The 2026 first extraordinary general meeting (the “**EGM**”) of Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”) was convened at 2:00 p.m. on Friday, October 9, 2026 at Room 302, 3/F, Building 4, No. 590 Ruiqing Road, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, PRC. References are made to the notice (the “**Notice**”) and the circular (the “**Circular**”) of the EGM of the Company both dated September 24, 2026. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The EGM was convened by the Board in accordance with the Company Law of the PRC and the Articles of Association, and chaired by Mr. Philip Li Wang, the Chairman of the Board and an executive director of the Company.

ATTENDANCE AT THE EGM

As at the date of the EGM, the Company did not hold any (i) treasury shares (including any treasury shares held or deposited with Central Clearing and Settlement System) established and operated by Hong Kong Securities Clearing Company Limited or (ii) repurchased Shares pending cancellation; and the total number of issued ordinary Shares was 243,417,100 Shares, comprising 235,703,422 H Shares and 7,713,678 Unlisted Foreign Shares, which was the total number of Shares entitling the Shareholders to attend and vote on the proposed resolutions at the EGM.

Shareholders (including proxies) representing 107,076,976 Shares (including 99,363,298 H Shares and 7,713,678 Unlisted Foreign Shares) or approximately 43.99% of the total issued Shares of the Company attended the EGM.

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the EGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM.

All Directors, namely Mr. Philip Li Wang, Mr. Yunqing Wang, Ms. Peili Wang, Mr. Yiqing Chen, Mr. Xubo Lu and Mr. Yifei Jiang attended the EGM either in person or by electronic means.

POLL RESULTS OF THE EGM

The poll results of the resolution proposed at the EGM are as follows:

Ordinary Resolution		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the proposal for the appointment of Ms. Qianwen Fei (費倩雯) as an independent non-executive director of the Company and to authorize the Board to fix her remuneration and to do all such acts and things to give effect to such matters.	107,076,976 (100%)	0 (0%)	0 (0%)

As more than half of the votes were cast in favour of Ordinary Resolution No. 1, the resolution proposed at the EGM was duly passed by way of poll by the Shareholders.

SCRUTINEERS

The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking. The representatives of the Shareholders participated in the scrutiny of the poll results.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

References are made to the announcement of the Company dated August 26, 2026 (the “**Announcement**”) and the Circular. Mr. Yiqing Chen (“**Mr. Chen**”) resigned as an independent non-executive Director due to his other business commitments with effect from the conclusion of the EGM. Mr. Chen has confirmed that he has no disagreement with the Board and there are no other matters related to his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange. The Board would like to express its sincere gratitude to Mr. Chen for his valuable contributions to the Board and the Company during his tenure of service.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Company is pleased to announce that Ms. Qianwen Fei (費倩雯) (“**Ms. Fei**”) was appointed as an independent non-executive Director with effect from October 9, 2026. Ms. Fei will hold office until the end of the current session of the Board.

The biographical details of Ms. Fei are set out in the Announcement and the Circular. As at the date of this announcement, there has been no change in such information.

As at the date of this announcement, save as disclosed above and in the Announcement and the Circular, Ms. Fei has confirmed that: (i) she is not related to any other Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) she does not hold and has not held any directorship in any other public companies whose shares were listed in Hong Kong or any overseas stock exchange in the past three years and does not have and has not held other major appointments or professional qualifications; (iii) she has not or is not deemed to have any interest in the shares or underlying shares of the Company or associated corporations (as defined in Part XV of the Securities and Futures Ordinance); (iv) she does not hold any other positions in the Company or other members of the Group; and (v) no other matters are required to be brought to the attention of shareholders of the Company or the Stock Exchange or required to be disclosed under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules.

Ms. Fei has confirmed (i) her independence to the Company by reference to the factors set out in Rule 3.13 of the Listing Rules; (ii) that she had no past or present financial or other interests in the business of the Company or its subsidiaries or any connection with any core connected persons (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect her independence at the time of her appointment.

Ms. Fei has entered into a service contract with the Company for a term commencing from the date of approval at the EGM and ending on the expiration of the term of the current session of the Board. The fee of remuneration for Ms. Fei will be fixed at RMB150,000 (before tax) per annum, which is determined by the Board with reference to her duties, experience and responsibilities in the Company as well as the prevailing market conditions.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

Following the resignation of Mr. Chen and the appointment of Ms. Fei, the composition of the Audit Committee and the Remuneration Committee shall be changed with effect from the conclusion of the EGM as follows:

- (i) Audit Committee: Mr. Yifei Jiang as the chairman in place of Mr. Chen and Ms. Fei as a member; and
- (ii) Remuneration Committee: Ms. Fei as a member in place of Mr. Chen.

Save as disclosed above, the composition of each Board committee remains unchanged.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive Director

Shanghai, the People's Republic of China, October 9, 2026

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Xubo LU, Mr. Yifei JIANG and Ms. Qianwen FEI as independent non-executive directors.